Characterization of the interaction of plasminogen activator inhibitor type 1 with vitronectin by surface plasmon resonance

Fibrinolysis and Proteolysis

Volumn 14, Issue 1, 2000, Pages 47-57

  Ehnebom, J ^a   Bjorquist P ^a   Sigurdardottir, O ^b   Deinum, J ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; VITRONECTIN;

ALPHA HELIX; ARTICLE; BINDING AFFINITY; BINDING SITE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DENATURATION; PROTEIN IMMOBILIZATION; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; STOICHIOMETRY; SURFACE PLASMON RESONANCE;

EID: 0034034952     PISSN: 13690191     EISSN: None     Source Type: Journal    
DOI: 10.1054/fipr.2000.0052     Document Type: Article

References (54)

1. van Meijer M, Pannekoek H. Structure of plasminogen activator inhibitor 1 (PAI-1) and its function in fibrinolysis - an update [Review]. Fibrinolysis 1995; 9: 263-276.
2. Potempa J, Korzus E, Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J Biol Chem 1994; 269: 15957-15960.
3. Strömqvist M, Karlsson KE, Björquist P et al. Characterisation of the complex of plasminogen activator inhibitor type 1 with tissue-type plasminogen activator by mass spectrometry and size-exclusion chromatography. Biochim Biophys Acta 1996; 1295: 103-109.
4. Chmielewska J, Ranby M, Wiman B. Kinetics of the inhibition of plasminogen activators by the plasminogen-activator inhibitor. Evidence for 'second-site' interactions. Biochem J 1988; 251: 327-332.
5. Björquist P, Brohlin M, Ehnebom J et al. Plasminogen activator inhibitor type-1 interacts exclusively with the proteinase domain of tissue plasminogen activator. Biochim Biophys Acta 1994; 1209: 191-202.
6. Declerck PJ, De Mol M, Vaughan DE, Collen D. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator. J Biol Chem 1992; 267: 11693-11696.
7. Sancho E, Declerck PJ, Price NC et al. Conformational studies on plasminogen activator inhibitor (PAI-1) in active, latent, substrate, and cleaved forms. Biochemistry 1995; 34: 1064-1069.
8. Ehnebom J, Pusa S, Björquist P, Deinum J. Comparison of chromogenic substrates for tissue plasminogen activator and the effects on the stability of plasminogen activator inhibitor type-1. Fibrinolysis 1997; 11: 287-293.
9. Mimuro J, Loskutoff DJ. Binding of type 1 plasminogen activator inhibitor to the extracellular matrix of cultured bovine endothelial cells. J Biol Chem 1989; 264: 5058-5063.
10. Declerck PJ, De Mol M, Alessi MC et al. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin). J Biol Chem 1988; 263: 15454-15461.
11. Lindahl TL, Sigurdardottir O, Wiman B. Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 1989; 62: 748-751.
12. Pusa S, Kristiansen C, Ehnebom J et al. Destabilisation of PAI-1 by chromogenic tPA substrates and protection by vitronectin. Thromb Haemost 1995; 73: 1010.
13. Sigurdardóttir O, Wiman B. Complex formation between plasminogen activator inhibitor 1 and vitronectin in purified systems and in plasma. Biochim Biophys Acta 1990; 1035: 56-61.
14. Preissner KT, Holzhuter S, Justus C, Muller-Berghaus G. Identification of and partial characterization of platelet vitronectin: evidence for complex formation with platelet-derived plasminogen activator inhibitor-1. Blood 1989; 74: 1989-1996.
15. Preissner KT. Structure and biological role of vitronectin. Ann Rev Cell Biol 1991; 7: 275-310.
16. Sigurdardóttir O, Wiman B. Studies on the interaction between plasminogen activator inhibitor-1 and vitronectin. Fibrinolysis 1992; 6: 27-32.
17. Gibson A, Baburaj K, Day DE et al. The use of fluorescent probes to characterize conformational changes in the interaction between vitronectin and plasminogen activator inhibitor-1. J Biol Chem 1997; 272: 5112-5121.
18. Fa M, Karolin J, Aleshkov S et al. Time-resolved polarized fluorescence spectroscopy studies of plasminogen activator inhibitor type 1-conformational changes of the reactive centre upon interactions with target proteases, vitronectin and heparin. Biochemistry 1995; 34: 13833-13840.
19. Lawrence DA, Berkenpas MB, Palaniappan S, Ginsburg D. Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J Biol Chem 1994; 269: 15223-15228.
20. Naski MC, Lawrence DA, Mosher DF et al. Kinetics of inactivation of alpha-thrombin by plasminogen activator inhibitor-1. J Biochem Chem 1993; 268: 12367-12372.
21. Stockmann A, Hess S, Declerck P et al. Multimeric vitronectin. Identification and characterization of conformation-dependent self-association of the adhesive protein. J Biol Chem 1993; 268: 22874-22882.
22. Lawrence DA, Palaniappan S, Stefansson S et al. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin - implications for the regulation of pericellular proteolysis. J Biol Chem 1997; 272: 7676-7680.
23. Seiffert D, Ciambrone G, Wagner NV et al. The somatomedin b domain of vitronectin. J Biol Chem 1994; 269: 2659-2666.
24. Björquist P, Ehnebom J, Inghardt T, Deinum J. Epitopes on plasminogen activator inhibitor type-1 important for binding to tissue plasminogen activator. Biochim Biophys Acta 1994; 1209: 191-202.
25. Björquist P, Ehnebom J, Inghardt T et al. Identification of the binding site for a low-molecular-weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis. Biochemistry 1998; 37: 1227-1234.
26. Björquist P, Ehenbom J, Deinum J. Protein movement during complex-formation between tissue plasminogen activator and plasminogen activator inhibitor type-1. Biochim Biophys Acta 1999; 35868:
27. Abrahamsson T, Björquist P, Deinum J et al. An antibody fragment against PAI-1 inhibits PAI-1 activity and stimulates fibrinolysis in vitro and in vivo. Fibrinolysis 1994; 8(SUPPL. 2): 55-56.
28. Abrahamsson T, Nenne V, Strömqvist M et al. Anti-thrombotic effect of a PAI-1 inhibitor in rats given endotoxin. Thromb Haemost 1996; 75: 118-126.
29. Strömqvist M, Andersson JO, Boström S et al. Separation of active and inactive forms of recombinant human plasminogen activator inhibitor type 1 (PAI-1) expressed in Chinese hamster ovary cells: comparison with native human PAI-1. Protein Expr Purif 1994; 5: 309-316.
30. Xue YF, Björquist P, Inghardt T et al. Interfering with the inhibitory mechanism of serpins - crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive-centre loop peptide. Structure 1998; 6: 627-636.
31. Dahlbäck B, Podack ER. Characterization of human s protein, an inhibitor of the membrane attack complex of complement. Demonstration of a free reactive thiol group. Biochemistry 1985; 24: 2368-2374.
32. Stenberg E, Persson B, Roos H, Urbanniczky C. Quantitative determination of surface concentration of protein with surface plasmon resonance by using radiolabelled proteins. J Colloid Interface Sci 1991; 143: 513-526.
33. Glaser RW. Antigen-antibody binding and mass transport by convection and diffusion to a surface: a two-dimensional computer model of binding and dissociation kinetics. Anal Biochem 1993; 213: 152-161.
34. OShannessy D, Brigham-Burke M, Soneson KK et al. Determination of rate and equilibrium binding constants for macromolecular interactions using surface plasmon resonance: use of non-linear least squares analysis methods. Anal Biochem 1993; 212: 457-468.
35. Hall DR, Cann JR, Winzor DJ. Demonstration of an upper limit to the range of association rate constants amenable to study by biosensor technology based on surface plasmon resonance. Anal Biochem 1996; 235: 175-184.
36. Schuck P. Reliable determination of binding affinity and kinetics using surface plasmon resonance biosensors. Curr Op Biotechnol 1997; 8: 498-502.
37. Christensen LL. Theoretical analysis of protein concentration determination using biosensor technology under conditions of partial mass transport limitation. Anal Biochem 1997; 249: 153-164.
38. Karlsson R, Stahlberg R. Surface plasmon resonance detection and multispot sensing for direct monitoring of interactions involving low-molecular-weight analytes and for determination of low affinities. Anal Biochem 1995; 228: 274-280.
39. Karlsson R, Fält A. Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. J Immunol Methods 1997; 200: 121-133.
40. Seiffert D. Evidence that conformational changes upon the transition of the native to the modified form of vitronection are not limited to the heparin binding domain. FEBS Letters 1995; 368: 155-159.
41. Zhuang P, Li H, Williams JG, Wagner NV et al. Characterization of the denaturation and renaturation of human plasma vitronectin. 2. Investigation into the mechanism of formation of multimers. J Biol Chem 1996; 271: 14333-14343.
42. Salonen EM, Vaheri A, Pollanen J et al. Interaction of plasminogen activator inhibitor (PAI-1) with vitronectin. J Biol Chem 1989; 264: 6339-6343.
43. Underwood PA, Steele JG, Dalton BA. Effects of polystyrene surface chemistry on the biological activity of solid phase fibronectin and vitronectin, analysed with monoclonal antibodies. J Cell Sci 1993; 104: 793-803.
44. Seiffert D, Loskutoff DJ. Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin b domain of vitronectin. J Biol Chem 1991; 266: 2824-2830.
45. Preissner KT, Grulich-Henn J, Ehrlich HJ et al. Structural requirements for the extracellular interaction of plasminogen activator inhibitor 1 with endothelial cell matrix-associated vitronectin. J Biol Chem 1990; 265: 18490-18498.
46. Wright HT. The structural puzzle of how serpin serine proteinase inhibitors work. Bioessays 1996; 18: 453-464.
47. van Meijer M, Stoop A, Smilde A et al. The composition of complexes between plasminogen activator inhibitor 1, vitronectin and either thrombin or tissue-type plasminogen activator. Thromb Haemost 1997; 77: 516-521.
48. Keijer J, Linders M, van Zonneveld A-J et al. The interaction of plasminogen activator inhibitor 1 with plasminogen activators (tissue-type and urokinase-type) and fibrin: Localization of interaction sites and physiologic relevance. Blood 1991; 78: 401-409.
49. van Meijer M, Gebbink RK, Preissner KT, Pannekoek H. Determination of the vitronectin binding site on plasminogen activator inhibitor 1 (PAI-1). FEBS Letters 1994; 352: 342-346.
50. van Zonneveld AJ, van den Berg BM, van Meijer M, Pannekoek H. Identification of functional interaction sites on proteins using bacteriophage-displayed random epitope libraries. Gene 1995; 167: 49-52.
51. Perrie AM, MacGregor IR, Booth NA. Definition of epitopes within plasminogen activator inhibitor type-1 (PAI-1) using multiple peptide synthesis. Fibrinolysis 1993; 7: 257-263.
52. MacGregor IR, Tonner AM, Micklem LR et al. Murine monoclonal antibodies against active site epitopes on human endothelial plasminogen activator inhibitor (pai-1). Fibrinolysis 1990; 4: 27-34.
53. Loskutoff DJ, Curriden SA, Hu G, Deng G. Regulation of cell adhesion by PAI-1. Apmis 1999; 107: 54-61.
54. Aertgeerts K, de Bondt HI, de Ranter C, Declerck PJ. Crystallization and X-ray diffraction data of the cleaved form of plasminogen activator inhibitor-1. Proteins 1995; 23: 118-121.